Hello, everyone, and a very good morning to you. A spot of rain is falling on the Pharmalot corporate campus this morning, but the weeds need watering, so... no complaints. Meanwhile, we are getting started on another busy day with a fresh stack of documents to peruse and phones calls to make. And there are those meetings coming up. We know you relate. After all, this is the mid-week point. So grab a cup of stimulation - this is a ritual, of course - and check out a few tidbits gathered for you. Hope your day goes well and catch you soon...
FDA Panel Votes Against Regeneron Gout Drug (Pharma Times)
Gilead Quad Pill Raises Kidney Concerns: FDA Staff (Bloomberg News)
Psychiatry Group Backs Down On Two DSM Diagnoses (New York Times)
Glaxo Begins $2.6B Hostile Offer For Human Genome (Bloomberg News)
Patheon To Close UK Plant & Eliminate 91 Jobs (Contract Pharma)
Gilead Truvada May Help Lower HIV Risk: FDA Staff (Reuters)
A New Debate Over NHS Price Cap On New Drugs (Financial Times)
Merck KGgA Workers Petition To Keep Plant Open (World Radio Switzerland)
Pfizer To Invest $130M In Belgian Facility (Expatica)
EDITOR'S NOTE: Please check this post for updates
rain pic thx to sterlic on flickr